Methotrexate exposure impacts cognitive processes cancer survivors need to multitask

June 6, 2016, St. Jude Children's Research Hospital
Yin Ting Cheung, Ph.D., postdoctoral research associate and Kevin Krull, Ph.D., faculty member of the Epidemiology / Cancer Control Department at St. Jude Children's Research Hospital. Credit: St. Jude Children's Research Hospital / Seth Dixon

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization and related skills as long-term survivors. The findings appear online today in an early release article in the Journal of Clinical Oncology.

Investigators also reported that brain imaging showed that higher of methotrexate during treatment for acute lymphoblastic leukemia (ALL) were associated with anatomical and functional changes in regions of the brain involved with mental flexibility, planning, reasoning and other skills related to executive functioning. Brain imaging documented several changes, including increased activity in the frontal lobe region. The finding suggests survivors' brains may be working harder to compensate for impaired cognitive functioning.

"With five-year survival rates for pediatric ALL approaching 95 percent, researchers are focused on better understanding and reducing the neurotoxicity patients still experience during and sometimes long after treatment," said first and corresponding author Kevin Krull, Ph.D., a member of the St. Jude Department of Epidemiology and Cancer Control. "It remains a relatively common problem even in the contemporary treatment era of chemotherapy only.

"This study is the first to show a clear dose-response effect between methotrexate concentrations in the blood during treatment and executive functioning in survivors. This information is essential for designing effective intervention to address the risk," he said.

The study included 218 long-term pediatric ALL survivors treated with multi-drug chemotherapy delivered directly to cerebrospinal fluid (intrathecal) rather than brain irradiation to prevent cancer from recurring in the central nervous system. The participants were enrolled in the St. Jude Total Therapy XV clinical trial between 2000 and 2010. All had survived at least five years from their diagnosis and were at least 8 years old when this study was done.

Methotrexate is one of the few chemotherapy agents that cross from the blood into the brain and nervous system. Previous research into a possible association between chemotherapy agents like methotrexate and neurotoxicity used the dose patients received as a surrogate for drug exposure as measured by blood levels of the drug. Those studies yielded conflicting results, possibly due to individual differences in methotrexate metabolism.

In this study, researchers calculated methotrexate concentrations by measuring blood levels of the drug before, during and after treatment. In addition to methotrexate, investigators also checked blood levels of the amino acid homocysteine, a marker of methotrexate activity, and the chemotherapy agent dexamethasone.

Higher concentrations of methotrexate and homocysteine were associated with lower scores on measures of executive function, including , verbal fluency, working memory and processing speed. While the impact varied, scores suggest some survivors had executive functioning that was moderately to almost severely impaired.

Along with increased activity in regions of the brain associated with executive functioning, brain imaging showed higher methotrexate exposure was associated with thicker brain cortex in prefrontal regions, which may suggest disrupted neuronal pruning that occurs with normal aging. Methotrexate exposure was also linked to changes in the white matter that insulates neural connections in the same region.

"The neural connections remain, but as the concentrate of methotrexate in the blood increases, the integrity of the white matter breaks down, which could affect functions like processing speed," Krull said.

The methotrexate risk was unrelated to the survivors' gender, age at diagnosis or disease risk group. In contrast, dexamethasone levels were not linked to executive function or other cognitive skills.

"Methotrexate has contributed to historically high cure rates for childhood leukemia," Krull said. "While physicians may look for opportunities to reduce concentrations of the drug in the future, interventions are already in development to enhance executive function in patients on therapy as well as long-term childhood cancer survivors."

For example, Krull is principal investigator of a pilot study into whether electrical stimulation of the prefrontal cortex combined with cognitive training will enhance in adult survivors of childhood leukemia.

Explore further: Prednisone use linked to increased risk of mortality in RA

More information: Journal of Clinical Oncology, DOI: 10.1200/JCO.2015.65.4574

Related Stories

Prednisone use linked to increased risk of mortality in RA

May 27, 2016
(HealthDay)—For patients with rheumatoid arthritis (RA), prednisone use is associated with an increased risk of mortality, according to a study published in the May issue of Arthritis Care & Research.

Relapses of childhood leukemia improve with high doses of common chemo drug

April 25, 2016
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of ...

Studies examine long-term outcomes in childhood, young adult cancer survivors

November 19, 2015
JAMA Oncology published two studies and a related editorial focused on long-term outcomes in survivors of childhood or young adult cancer.

Attention problems persist in childhood leukemia survivors treated with chemotherapy alone

February 10, 2016
Pediatric acute lymphoblastic leukemia (ALL) patients treated with chemotherapy alone remain at risk for attention and learning problems that persist after treatment ends, according to St. Jude Children's Research Hospital ...

Altered brain connectivity may explain cognitive impairment in pediatric leukemia survivors

May 18, 2016
The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that ...

Drug helps brain tumor patients live longer

January 28, 2008
People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the January 29, 2008, ...

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Inflammatory bowel disease linked to prostate cancer

December 7, 2018
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.